<span id="b3inl"></span>
  • <i id="b3inl"><meter id="b3inl"></meter></i><rt id="b3inl"><optgroup id="b3inl"><strike id="b3inl"></strike></optgroup></rt>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>

    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
        您好!歡迎訪問貝達(dá)藥業(yè)官方網(wǎng)站。
        服務(wù)熱線:0571-86130357     加入收藏 | 在線反饋English
        新聞中心 / News Center
        《CHINA DAILY》:Betta applauds supportive moves in pharma sector
        日期: 2025-03-13

        Employees of Betta Pharmaceuticals work on a drug packaging line in Hangzhou, Zhejiang province. WANG GANG/CHINA NEWS SERVICE


        Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, challenging foreign monopolies and positioning themselves as leaders in global biopharma, said a national political adviser on the sidelines of the two sessions that ended on Tuesday.

        Ding Lieming, a member of the 14th National Committee of the Chinese People's Political Consultative Conference and chairman of Betta Pharmaceuticals Co Ltd, a leading innovative biopharma firm, recalled a pivotal moment in his company's rise in an interview with China Daily. In 2005, Betta faced a significant roadblock while submitting a clinical trial application for its oncology drug.

        The approval process at that time took up to two years, a timeline that hindered the company's R&D efforts. After turning to the Zhejiang provincial government for support, Betta's request was expedited, and approval was cut to just seven months.

        "As competition in the biopharma industry intensifies globally, China is leveraging its growing capabilities to take on established foreign players and reshape the global market," Ding said.

        Ding Lieming

        The company has set its sights on global markets, Ding added. In December, the United States approved Ensartinib, making it the first small-molecule targeted therapy for lung cancer independently developed and globally launched by a Chinese company.

        "We have also begun filing for approval of such drugs in Europe, marking a significant milestone in the company's international expansion," he disclosed.

        Founded in 2003, Betta has championed homegrown innovation, focusing on developing therapies that can compete internationally. Conmana, the company's flagship product and China's first small-molecule targeted cancer treatment, was approved in 2011 and has already improved the lives of over 700,000 lung cancer patients.

        While China's pharmaceutical industry is accelerating its global presence, Ding said that hurdles still remain, particularly in financing.

        He said: "Greater cooperation between government-led funds and industry investors is needed to bolster confidence in the pharmaceutical sector. It is also important to create flexible investment mechanisms and adopt long-term strategies to nurture patient capital that supports extended innovation cycles."

        Despite these challenges, Ding stressed the need to strengthen China's innovation ecosystem by fostering closer ties between academic research institutions and the pharmaceutical industry.

        To succeed on the global stage, Ding advocates a dual strategy: continuing to prioritize homegrown innovation, especially in cutting-edge fields like small-molecule targeted drugs, gene therapy and immunotherapy, while deepening international partnerships with global pharmaceutical companies, research institutions and regulatory agencies.

        Looking ahead, Ding said there were immense opportunities in leveraging China's advantages — its vast patient base, efficient supply chains and rapidly evolving approval processes.

        "Technological innovation is reshaping the global biopharma landscape," Ding said. "For Chinese companies to succeed, they must fully integrate into the international innovation ecosystem and challenge established global players head-on."


        上一條: 無
        下一條: 《中國日?qǐng)?bào)網(wǎng)》:從2年到7個(gè)月:中國創(chuàng)新藥如何闖關(guān)全球市場?
        熱門點(diǎn)擊
        主站蜘蛛池模板: 中字幕视频在线永久在线观看免费 | 亚洲a级在线观看| 中文字幕永久免费视频| 国产女高清在线看免费观看| 亚洲一级免费毛片| 亚欧免费视频一区二区三区| 亚洲av无码成h人动漫无遮挡| www在线观看免费视频| 免费一级毛片不卡在线播放| 亚洲AV无码男人的天堂| 亚洲AV午夜成人片| 日日躁狠狠躁狠狠爱免费视频| 国产青草视频免费观看97| 亚洲国产精品网站在线播放| 成人性生活免费视频| 四虎永久在线精品视频免费观看| 亚洲欧洲久久精品| 91麻豆最新在线人成免费观看| 亚洲色成人网一二三区| 最近最新高清免费中文字幕| 久久久久亚洲av无码专区导航| 免费国产黄网站在线观看 | 无码国产精品一区二区免费 | 日本大片在线看黄a∨免费| 亚洲精品无码久久久久久| a级毛片视频免费观看| 国产亚洲成av片在线观看| 最近免费中文字幕MV在线视频3 | 亚洲a∨无码精品色午夜| 免费A级毛片无码A∨男男| 免费在线观看自拍性爱视频| 成人亚洲性情网站WWW在线观看| a级毛片高清免费视频| 亚洲专区先锋影音| 一二三四在线播放免费观看中文版视频 | 亚洲精品视频专区| 91免费精品国自产拍在线不卡| 精品国产亚洲第一区二区三区 | 真人做A免费观看| 亚洲欧美中文日韩视频| 亚洲精品一级无码中文字幕|